GlassScriptPhysician profile
Benjamin Blake Weathersby
NPI 1730182932
$14,356.70
in general payments reported to CMS, 2019-2025
32 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $236 · 2021: $188 · 2022: $618 · 2023: $983 · 2024: $992 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,613 · Food and Beverage: $3,686 · Education: $190 · Travel and Lodging: $112 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,612.53 |
| Food and Beverage | $3,686.11 |
| Education | $189.80 |
| Travel and Lodging | $111.91 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $4,990.83 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $4,683.09 | 2024-2025 | |
| Vifor Pharma, INC. | $1,009.82 | 2019-2024 | Veltassa |
| Mallinckrodt Hospital Products INC. | $351.15 | 2020-2025 | Acthar |
| Opko Pharmaceuticals, LLC | $317.11 | 2019-2024 | Rayaldee |
| Aurinia Pharma U.S., INC. | $280.43 | 2022-2025 | Lupkynis |
| Travere Therapeutics, INC. | $244.47 | 2022-2025 | |
| Baxter Healthcare | $239.37 | 2019-2023 | Renal - Pd |
| Nxstage Medical, INC. | $223.14 | 2024 | |
| Vantive US Healthcare LLC | $218.14 | 2025 | Renal - Pd |
| Janssen Pharmaceuticals, INC | $208.39 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $201.30 | 2019-2024 | Farxiga |
| Medtronic, INC. | $180.00 | 2021-2025 | Symplicity G3 |
| Amgen INC. | $177.18 | 2019-2024 | Parsabiv, Epogen, Tavneos |
| W. L. Gore & Associates, INC. | $123.12 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $122.23 | 2019-2025 | Jynarque |
| Novo Nordisk INC | $97.72 | 2024-2025 | Ozempic, Rybelsus, Rivfloza |
| Alnylam Pharmaceuticals INC. | $97.39 | 2022-2025 | Onpattro |
| Akebia Therapeutics INC | $82.92 | 2023-2024 | Auryxia, Vafseo |
| Ani Pharmaceuticals, INC. | $59.84 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $59.83 | 2024-2025 | |
| Shire North American Group INC | $59.24 | 2019 | |
| Glaxosmithkline, LLC. | $54.00 | 2023 | Benlysta, Jesduvroq |
| Kyowa Kirin, INC. | $49.74 | 2023-2024 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.07 | 2024-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $36.51 | 2019-2025 | Velphoro |
| Cormedix INC. | $35.65 | 2025 | Defencath |
| Ardelyx, INC. | $28.25 | 2024 | Ibsrela |
| Mallinckrodt Enterprises LLC | $26.25 | 2019 | |
| Horizon Therapeutics Plc | $20.39 | 2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $19.58 | 2023 | |
| Alexion Pharmaceuticals, INC. | $14.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Weathersby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.